Literature DB >> 17900799

Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases A SPECT study with partial volume effect correction.

Renaud David1, Malick Koulibaly, Michel Benoit, René Garcia, Hervé Caci, Jacques Darcourt, Philippe Robert.   

Abstract

OBJECTIVES: The aim of the present study was to stress the relationship between neuropsychiatric symptoms and most particularly apathy and striatal dopamine uptake in patients with Alzheimer's disease (AD) or dementia with Lewy body (DLB). PATIENTS AND METHODS: Twenty-two patients (AD n=14; DLB n=8) were included. All patients had neuropsychological and behavioral examination including Mini Mental Test Examination (MMSE), Neuropsychiatric Inventory (NPI), and UPDRS for the motor activity assessment. Apathy dimensions, emotional blunting, lack of initiative and lack of interest were assessed using the Apathy Inventory (AI). Dopamine transporter (DAT) striatal uptake was assessed using (123)I-FP-CIT (DaTSCAN) SPECT. Quantitative measurements were obtained in 3D using a method which compensates for physical detection biases including partial volume effect.
RESULTS: We observed a correlation between DAT uptake and NPI's domains only for apathy. More specifically using the AI, lack of initiative significantly correlated with bilateral putamen DAT uptake. Using partial correlation coefficients controlling for the UPDRS score, the correlation remained significant between lack of initiative and right and left putamen DAT uptake.
CONCLUSION: These results demonstrate a relationship between apathy and DAT levels independent from motor activity. They suggest that the patients with neurodegenerative diseases presenting with apathy are characterized by some degree of dopaminergic neuronal loss.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17900799     DOI: 10.1016/j.clineuro.2007.08.007

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  32 in total

Review 1.  REVIEW: Apathy diagnosis, assessment, and treatment in Alzheimer's disease.

Authors:  Philippe H Robert; Emmanuel Mulin; Patrick Malléa; Renaud David
Journal:  CNS Neurosci Ther       Date:  2010-10       Impact factor: 5.243

2.  Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.

Authors:  Paul B Rosenberg; Krista L Lanctôt; Lea T Drye; Nathan Herrmann; Roberta W Scherer; David L Bachman; Jacobo E Mintzer
Journal:  J Clin Psychiatry       Date:  2013-08       Impact factor: 4.384

Review 3.  Apathy in neuropsychiatric disease: diagnosis, pathophysiology, and treatment.

Authors:  Thomas N Chase
Journal:  Neurotox Res       Date:  2010-05-15       Impact factor: 3.911

Review 4.  Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits?

Authors:  Paul B Rosenberg; Milap A Nowrangi; Constantine G Lyketsos
Journal:  Mol Aspects Med       Date:  2015-06-03

Review 5.  Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.

Authors:  Kentaro Hirao; Gregory M Pontone; Gwenn S Smith
Journal:  Neurosci Biobehav Rev       Date:  2014-11-20       Impact factor: 8.989

6.  LeSCoD: a new clinical scale for the detection of Lewy body disease in neurocognitive disorders.

Authors:  Pauline Olivieri; Thibaud Lebouvier; Jean-Benoît Hardouin; Hélène Courtemanche; Séverine Le Dily; Laëtitia Barbin; Amandine Pallardy; Pascal Derkinderen; Claire Boutoleau-Bretonnière
Journal:  J Neurol       Date:  2021-04-08       Impact factor: 4.849

7.  Dose-dependent effects of ladostigil on microglial activation and cognition in aged rats.

Authors:  Marta Weinstock; Corina Bejar; Donna Schorer-Apelbaum; Rony Panarsky; Lisandro Luques; Shai Shoham
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-17       Impact factor: 4.147

8.  Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease.

Authors:  Suzanne Reeves; Richard Brown; Robert Howard; Paul Grasby
Journal:  Neurology       Date:  2009-02-10       Impact factor: 9.910

9.  Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial.

Authors:  Krista L Lanctôt; Sarah A Chau; Nathan Herrmann; Lea T Drye; Paul B Rosenberg; Roberta W Scherer; Sandra E Black; Vijay Vaidya; David L Bachman; Jacobo E Mintzer
Journal:  Int Psychogeriatr       Date:  2013-10-29       Impact factor: 3.878

Review 10.  A review of neuroimaging findings of apathy in Alzheimer's disease.

Authors:  Christos Theleritis; Antonios Politis; Kostas Siarkos; Costantine G Lyketsos
Journal:  Int Psychogeriatr       Date:  2013-10-18       Impact factor: 3.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.